Hi David
The type ot reaction that Michael describes appears to be so rare that it wasn't reported during the research studies.
It has only been reported after approval and therefore is unlikely to be included in either the patient leaflet or the full prescribing information.
If annecdotal reports continue, the original studies might be looked at again, and at some point the lable may get changed.
Howver, I thought this improtant enough to include this in the i-Base information about dolutegravir and Triumeq:
Dolutegravir
http://i-base.info/guides/8851Triumeq
http://i-base.info/guides/10303Also, the short i-Base summares for every drug include a link at the bottom to the Euriopean patient and prescribing information - and translations are usually available in most European languages.
EACS (European) guidelines are likely to include this in their next update.